This phase II trial's aim is to assess BMS‐986278 in IPF patients or IPF‐ILD patients given that the antagonism of LPA1 was proven to be helpful in IPF patients. This evidence concerns the gene LPAR1 and idiopathic pulmonary fibrosis.